Protheragen Obesity



GSK1904529A

Cat. No.:	OB0225WX-2393
Appearance:	Solid
Purity:	≥99%
Identity:	Confirmed by NMR, and HPLC.
Size:	10 mg; 50 mg; 1 g

This product is for research use only and is not intended for diagnostic use.

Product Overview

Description	GSK1904529A is a high-affinity dual inhibitor of IGF-1R and IR (IC50: 27 nM and 25 nM) with more than 100-fold selectivity over Akt, Aurora, and CDK kinases.
Synonym	GSK 4529; 1089283-49-7; GSK-1904529A; *N*-(2,6-Difluorophenyl)-5-[3-[2-[[5- ethyl-2-(methyloxy)-4-[4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-2-(methyloxy)benzamide; GSK 19 04529A; IGF-1R inhibitor GS1904529A; *N*-(2,6-difluorophenyl)-5-(3-(2-((5-e thyl-2-methoxy-4-(4-(4-(methylsulfonyl)piperazin-1-yl)piperidin-1-yl)phenyl)amin o)pyrimidin-4-yl)imidazo[1,2-a]pyridin-2-yl)-2-methoxybenzamide; *N*-(2,6-d ifluorophenyl)-5-(3-(2-(5-ethyl-2-methoxy-4-(4-(4-(methylsulfonyl)piperazin-1-yl)piperidin-1-yl)phenylamino)pyrimidin-4-yl)imidazo[1,2-a]pyridin-2-yl)-2-methoxy benzamide; *N*-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-meth ylsulfonylpiperazin-1-yl)piperidin-1-yl]anilino]pyrimidin-4-yl]imidazo[1,2-a]pyr idin-2-yl]-2-methoxybenzamide; *N*-(2,6-difluorophenyl)-5-(3-{2-[(5-ethyl-2 -(methyloxy)-4-{4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl}phenyl)amino] -4-pyrimidinyl}imidazo[1,2-a]pyridin-2-yl)-2-(methyloxy)benzamide; MFCD17010271; *N*-(2,6-Difluorophenyl)-5-[3-[2-[[5-ethyl-2-(methyloxy)-4-[4-[4-(methylsu lfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]imidazo[1,2-a]p yridin-; *N*-(2,6-difluorophenyl)-5-{3-[2-({5-ethyl-4-[4-(4-methanesulfonyl piperazin-1-yl)piperidin-1-yl]-2-methoxyphenyl}amino)pyrimidin-4-yl]imidazo[1,2- a]pyridin-2-yl}-2-methoxybenzamide
CAS No.	1089283-49-7

Address: 101-4 Colin Dr, Holbrook, NY 11741, USA
Phone: 1-631-506-1393
info@obesityscientific.com

Protheragen
Obesity



Compound CID	25124816
Formula	$C_{44}H_{47}F_2N_9O_5S$
Formula Weight	851.96

Specification

IUPAC Name	*N*-(2,6-Difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonylp iperazin-1-yl)piperidin-1-yl]anilino]pyrimidin-4-yl]imidazo[1,2-a]pyridin-2-yl]- 2-methoxybenzamide
InChI	InChI=1S/C44H47F2N9O5S/c1-5-28-26-35(38(60-3)27-36(28)53-19-15-30(16-20-53)52-21-23-54(24-22-52)61(4,57)58)49-44-47-17-14-34(48-44)42-40(50-39-11-6-7-18-55(39)42)29-12-13-37(59-2)31(25-29)43(56)51-41-32(45)9-8-10-33(41)46/h6-14,17-18,25-27,30H,5,15-16,19-24H2,1-4H3,(H,51,56)(H,47,48,49)
InChI Key	MOSKATHMXWSZTQ-UHFFFAOYSA-N
SMILES string	CCC1=CC(=C(C=C1N2CCC(CC2)N3CCN(CC3)S(=O)(=O)C)OC)NC4=NC=CC(=N4)C5=C(N=C6N5C=CC=C6)C7=CC(=C(C=C7)OC)C(=O)NC8=C(C=CC=C8F)F
Stability	3 years in powder form.
Storage	Storage at -20°C.
Applications	GSK1904529A is utilized in pharmacological research as a selective small-molecul e inhibitor of IGF-1R to investigate the regulation of metabolic signaling and t he suppression of ligand-induced receptor phosphorylation.

Library Information

Target	IGF-1R
Receptor	IGF-1R
Pathways	Protein tyrosine kinase
Plate Number	L6700-01
Empty Location	a1-h1; a12-h12
Container	96-well plate
Formulation	10mM DMSO
DMSO Max Solubility	124 mg/mL; 145.55 mM
ALogP	6.571
HBA_Count	8
HBD_Count	2
Rotatable Bond	12

Address: 101-4 Colin Dr, Holbrook, NY 11741, USA
Phone: 1-631-506-1393
info@obesityscientific.com